Kanan Alshammari

Kanan Alshammari

Auto-generated profile, based on publicly available information

Kanan Alshammari

Department of Oncology, Ministry of National Guard—Health Affairs, Riyadh, Saudi Arabia

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2023 in Cancers
Verified
Journal Article
Open access
PDF file
KAKanan Alshammari
Kanan Alshammari
FAFaizah Alotaibi
Faizah Alotaibi
FAFutoon Alsugheir
Futoon Alsugheir
MAMohammad Aldawoud
Mohammad Aldawoud
AAAshwaq Alolayan
Ashwaq Alolayan
ASAbdullah S. Al Saleh
Abdullah S. Al Saleh
Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide with a poor prognosis. Treatment with immune checkpoint inhibitors (ICIs) has improved overall survival in patients with HCC. However, not all patients benefit from the treatment. In this study, 59 patients with HCC were enrolled from two medical centers in Saudi Arabia, with 34% using antibiotics concurrently with their Nivolumab (anti-PD1 blockade). The impact of antibiotic use on the clinical outcomes of patients with HCC undergoing treatment with anti-PD1 blockade was examined. The patients’ overall survival (OS) was 5 months (95% CI: 3.2, 6.7) compared to 10 months (95% CI: 0, 22.2) (p = 0.08). Notably, patients with Child–Pugh A cirrhosis receiving anti-PD1 blockade treatment without concurrent antibiotic use showed a significantly longer median OS reaching 22 months (95% CI: 6.5, 37.4) compared to those who were given antibiotics with a median OS of 6 months (95% CI: 2.7, 9.2) (p = 0.02). This difference in overall survival was particularly found in Child–Pugh class A patients receiving anti-PD1 blockade. These findings suggest that antibiotic use may negatively affect survival outcomes in HCC patients undergoing anti-PD1 blockade, potentially due to antibiotic-induced alterations to the gut microbiome impacting the anti-PD1 blockade response. This study suggests the need for careful consideration when prescribing antibiotics to patients with HCC receiving anti-PD1 blockade.

1 December 2021 in Clinical Colorectal Cancer
Verified
Journal Article
Open access
KAKanan Alshammari
Kanan Alshammari
KAKyaw L. Aung
Kyaw L. Aung
TZTong Zhang
Tong Zhang
ARAlbiruni R.A. Razak
Albiruni R.A. Razak
SSStefano Serra
Stefano Serra
PBPhilippe L. Bedard
Philippe L. Bedard
MEK inhibition may overcome resistance to EGFR inhibition in patients with RAS wildtype (wt) metastatic colorectal cancer (mCRC). We evaluated antitumor activity of trametinib (MEK1/2 inhibitor) with panitumumab (EGFR monoclonal antibody) in a phase II trial. Patients with KRAS, NRAS, and BRAF wt mCRC with prior 5-FU, irinotecan, oxaliplatin, +/- bevacizumab and no prior anti-EGFR therapy were treated with trametinib 1.5 mg oral daily and panitumumab 4.8 mg/kg IV every 2 weeks. Primary endpoint was clinical benefit rate (CB; CR, PR, or SD ≥24 weeks) by RECIST v1.1. A 2-stage minimax design was used. Serial plasma circulating free DNA (cfDNA) was collected and profiled using Oncomine Lung cfDNA assay. Fourteen patients were enrolled from November 2015 to April 2019. CB rate was 38% (5/13) and median progression free survival (PFS) was 4.4 months (95% CI, 2.9-7.1). Confirmed overall response rate was 38% (5/13). Treatment-related AE (trAE) included acneiform rash (85%), diarrhea (62%), maculopapular rash (54%), mucositis (46%), and others. Dose modifications and interruptions of trametinib occurred in 69% and panitumumab in 54% of patients. The trial did not progress to stage II accrual due to tolerability and short duration of response. RAS or BRAF mutations cfDNA were detected in 3/13 patients (23%) before radiographic disease progression. The addition of trametinib to panitumumab led to a high rate of tumor shrinkage in RAS/RAF wt metastatic colorectal cancer, with poor tolerability due to a high incidence of skin toxicity. Median PFS was similar to panitumumab alone in historical control data.

1 July 2025 in Journal of Hepatocellular Carcinoma
Verified
Journal Article
Open access
MAMohamed Asiri
Mohamed Asiri
ABAbdullah BinAbdu
Abdullah BinAbdu
AAAbdulrahman Al-Ammar
Abdulrahman Al-Ammar
AAAbdulaziz Alsuaib
Abdulaziz Alsuaib
AAAbdullah Al-Shehri
Abdullah Al-Shehri
KAKanan Alshammari
Kanan Alshammari
To investigate survival outcomes and prognostic factors of systemic therapies in advanced hepatocellular carcinoma (HCC) within Saudi Arabia, addressing the limited regional data. A retrospective review of 670 HCC patients was utilized. 130 patients with advanced HCC who received first-line systemic therapy were identified, and data on demographics, tumor characteristics, treatment regimens, laboratory findings, and survival outcomes were collected. Treatment response and survival outcomes were evaluated using RECIST criteria and the Kaplan-Meier method, respectively. Our population's mean age was 70.4, majority being males. Sorafenib was the most frequently used, then nivolumab and the atezolizumab-bevacizumab (Atezo+Bev) combination. Median overall survival (OS) varied by treatment: patients receiving Atezo+Bev showed the longest OS, followed by nivolumab and sorafenib. No statistically significant difference was observed in survival. Despite the small sample size, this trend suggests a potential OS benefit with Atezo+Bev, particularly in patients with advanced hepatic dysfunction. Furthermore, 39.1% of patients had elevated alpha-fetoprotein (AFP) levels and 26.8% had sarcopenia. Multivariate analysis highlighted the elevated neutrophil-to-lymphocyte ratio (NLR) as a significant predictor of worse survival, reinforcing its relevance as a prognostic marker in HCC. Although sarcopenia demonstrated an improved survival trend, it was not statistically significant. Adverse events were consistent, with elevated AST, anorexia, and fatigue frequently observed. This study illustrated Atezo+Bev's potential in improving OS in advanced HCC, with an elevated NLR identified as a key marker for poor prognosis. These findings support the need for prospective studies to confirm and expand regional insights into the management of HCC.

1 January 2024 in Clinical Medicine Insights: Oncology
Verified
Journal Article
Open access
RARakan Bandar Alanazi
Rakan Bandar Alanazi
AAAhmed Aljizeeri
Ahmed Aljizeeri
AAAhmed Alsaileek
Ahmed Alsaileek
AAAzzam Alrashid
Azzam Alrashid
AAAshwaq Alolayan
Ashwaq Alolayan
KAKanan Alshammari
Kanan Alshammari
Background: Soft tissue sarcoma (STS) is a rare malignancy that affects soft tissues. It encompasses various subtypes and requires different treatment strategies. Doxorubicin is a commonly used anthracycline in the management of localized and metastatic STS. However, high doses of doxorubicin are associated with cardiotoxicity, which can significantly impact patients’ long-term outcomes. This study aimed to evaluate doxorubicin’s effect on cardiac function in patients with sarcoma and to correlate the frequency of cardiotoxicity with potential risk factors. Methods: A retrospective analysis was conducted on patients with sarcoma who were treated with doxorubicin between 2016 and 2022 at King Abdulaziz Medical City in Saudi Arabia. Patient demographic information, comorbidities, cardiac measurements, laboratory values, systemic therapy, and treatment outcomes were collected from electronic medical records. A statistical analysis was performed to assess the association between cardiotoxicity and various factors. Results: A total of 133 patients were included in the study, with a median age of 30 years. Cardiotoxicity was observed in 9% of the patients. Female patients had a significantly higher risk of developing cardiotoxicity. Patients with a higher Eastern Cooperative Oncology Group (ECOG) performance status and lower troponin I levels also had an increased risk of cardiotoxicity. However, there was no significant association between cardiotoxicity and the number of chemotherapy cycles, total cumulative dose of doxorubicin, or history of radiation. Furthermore, patients with cardiotoxicity had a higher risk of mortality. The overall survival of the patients was 18 months. Conclusion: Doxorubicin-associated cardiotoxicity is a concern for patients with sarcoma. Female patients and patients with a higher ECOG performance status are at an increased risk of developing cardiotoxicity. Careful monitoring and risk assessment are crucial for mitigating the adverse effects of doxorubicin treatment in patients with sarcoma. Future studies are warranted to validate these findings and explore preventive strategies for doxorubicin-induced cardiotoxicity in patients with sarcoma.

29 June 2026 in Frontiers in Oncology
Verified
Journal Article
Open access
BABader Alshamsan
Bader Alshamsan
ETEmad Tashkandi
Emad Tashkandi
MAMohammed Alghamdi
Mohammed Alghamdi
AAAli H. Alfakeeh
Ali H. Alfakeeh
AAAli M. Alzahrani
Ali M. Alzahrani
KAKanan Alshammari
Kanan Alshammari
Purpose: Advanced biliary tract cancer (BTC) carries a poor prognosis, with limited regional data available. This study evaluated outcomes, treatment patterns, and prognostic factors in a multicenter cohort of patients with de novo advanced BTC. Methods: A retrospective cohort of 271 patients with de novo advanced biliary tract cancer diagnosed at five tertiary centers in Saudi Arabia (2016–2023) was analyzed. Clinical, pathological, treatment, and molecular data were extracted from electronic health records. Overall survival was estimated using the Kaplan–Meier analysis, and prognostic factors were assessed through multivariable Cox regression. Results: Systemic therapy was administered to 211 patients (77.9%). Among the entire cohort, 92 patients (33.9%) received second-line therapy, 25 (9.2%) received third-line therapy, and 8 (3.0%) received fourth-line therapy. Median overall survival (OS) was 9.5 months (95% CI, 8.4–10.6). On multivariable analysis, inferior OS was independently associated with poor ECOG performance status (PS 4: HR 4.08, P = 0.031), age 15–39 years (HR 4.44, P < 0.001), extrahepatic cholangiocarcinoma (HR 1.91, P = 0.017), cirrhosis (HR 3.13, P = 0.004), and elevated CEA (HR 1.92, P = 0.003). Patients with disease control had a 71% lower hazard of death (HR 0.29, 95% CI 0.18–0.47) and longer median OS (16.0 vs 7.7 months). Conclusions: Advanced BTC in Saudi Arabia demonstrates poor outcomes, with survival strongly influenced by performance status, age, tumor site, cirrhosis, and biomarkers. Treatment exposure was limited, with only one-third receiving second-line therapy, highlighting the urgent need for expanded access to immunotherapy and molecular profiling.

1 July 2026 in JCO Global Oncology
Verified
Journal Article
Open access
MAMohammad Alkaiyat
Mohammad Alkaiyat
KAKanan Alshammari
Kanan Alshammari
ACAnnibale Cois
Annibale Cois
PURPOSE: To assess willingness of patients with cancer to participate in observational studies (OBS) and clinical trials (CT) and to examine the factors influencing their decision to join CT. METHODS: A cross-sectional study using a systematic sampling strategy was conducted from December 2023 to June 2024. Data were collected directly from patients and their medical charts. Logistic regression was performed to identify significant predictors of patients' willingness to participate in CT. RESULTS: A total of 367 patients participated, 58.9% were females, and 59.8% had stage IV disease. Most participants (81%) had a performance status (PS) of 0-1, with only 1.9% having prior experience with a CT and 9% with OBS. Willingness to join OBS was higher than willingness to join CT (64% v 31.6%, P < .001). Key barriers included fear of side effects (61.6%), lack of information (46.3%), and concerns about the investigational product (41.6%). Motivators were having their treating physician as the principal investigator (42.5%) and prior human testing of the product (40.6%). Patients who underwent surgery or believed that their physical or psychological condition is unsuitable for trials were less likely to participate ( P < .05, odds ratio [OR], 0.30, 0.38, 0.37, respectively). Patients with a friend or relative who had joined a trial were more willing to participate ( P < .05, OR, 3.48). CONCLUSION: The results highlight a low level of willingness to participate in CT. Some barriers could be avoided during the study design phase. Discrepancies between patients' self-assessed PS and physicians' evaluations may lower the enrollment rates. Encouraging patients who have participated in CTs to share their experiences with the family and friends could significantly improve the community's willingness to join CT.